Maintenance hemodialysis patients with hyperphosphatemia
Conditions
Interventions
Patients will be treated for 24 weeks with ferric citrate hydrate switched from phosphate binder that has been used before entry.
Patients will be treated for 24weeks with previous phosphate binder us
Sponsors
Japan Tobacco Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients receiving hemodialysis 2) Patients receiving non-iron based phosphate binders. 3) Patients receiving a constant dose of ESA 4) Patients who provided voluntary informed consent to participate in the study
Exclusion criteria
Exclusion criteria: 1) Patients who have administrated of oral iron agents within 4weeks before entry. 2) Patients with uncontrolled serum P 3) Patients with uncontrolled serum Ca 4) Patients with uncontrolled serum Hb 5) Patients with uncontrolled hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in ESA dose from baseline to the end of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Cumulative dose of intravenous iron during the study. 2) Cumulative dose of ESA during the study. 3) ESA dose at each observation. 4) ERI at each observation. 5) Red blood cell related parameters at each observation. 6) Iron related parameters at each observation. 7) CKD-MBD related parameters at each observation. | — |
Countries
Japan
Contacts
Public ContactKotaro Senuki
Sogo Rinsho Medefi Co., Ltd Project promotion department
Outcome results
None listed